Basic Information
| LncRNA/CircRNA Name | PAR5 |
| Synonyms | Prader Willi/Angelman Region RNA5 |
| Region | GRCh38_15:24985053-24988232 |
| Ensemble | ENSG00000279192 |
| Refseq | NR_022008 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Anaplastic thyroid cancer |
| ICD-0-3 | C73 |
| Methods | qRT-PCR, RIP, Luciferase Assay, Western blot |
| Sample | human thyroid tissues,cell lines FRO and 8505c |
| Expression Pattern | down-regulated |
| Function Description | The lncRNA PAR5 Was Drastically Downregulated in ATC.PAR5 Overexpression Reduces Cell Proliferation of Thyroid Cancer Cell Lines.Restoration of PAR5 Expression Decreases Migratory Ability of Thyroid Cancer Cells.PAR5 not only reduces the EZH2 protein levels, but also decreases EZH2 binding to the E-cadherin promoter, thereby, affecting the expression of its target genes. |
| Pubmed ID | 31963578 |
| Year | 2020 |
| Title | The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 ( PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity |
External Links
| Links for PAR5 | GenBank HGNC NONCODE |
| Links for Anaplastic thyroid cancer | OMIM COSMIC |